185 related articles for article (PubMed ID: 37709204)
21. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
[TBL] [Abstract][Full Text] [Related]
23. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
27. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.
Molina JC; Steinberg SM; Yates B; Lee DW; Little L; Mackall CL; Shalabi H; Shah NN
Transplant Cell Ther; 2022 Jan; 28(1):31.e1-31.e9. PubMed ID: 34687939
[TBL] [Abstract][Full Text] [Related]
28. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.
Logue JM; Chavez JC
Curr Treat Options Oncol; 2021 Oct; 22(12):112. PubMed ID: 34697650
[TBL] [Abstract][Full Text] [Related]
29. Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Kaddu-Mulindwa D; Gödel P; Kutsch N; Heger JM; Scheid C; Borchmann P; Holtick U; Held G; Thurner L; Bewarder M; Rixecker T; Bittenbring JT
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e498-e506. PubMed ID: 35094950
[TBL] [Abstract][Full Text] [Related]
30. Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.
Ababneh HS; Ng AK; Frigault MJ; Abramson JS; Johnson PC; Jacobson CA; Patel CG
Haematologica; 2023 Nov; 108(11):2972-2981. PubMed ID: 37317884
[TBL] [Abstract][Full Text] [Related]
31. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
33. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
González-Barca E; Boumendil A; Blaise D; Trněný M; Masszi T; Finel H; Michieli MG; Bittenbring JT; Gritti G; Snowden JA; Bishton M; Bruno B; de Villambrosia SG; Janikova A; Leleu X; Anagnostopoulos A; Poiré X; Crysandt M; Özkurt ZN; Vandenberghe E; Itälä-Remes M; Cahn JY; Jantunen E; Schroyens W; Maertens J; Esquirol A; Dreger P; Montoto S; Sureda A
Bone Marrow Transplant; 2020 Feb; 55(2):393-399. PubMed ID: 31541205
[TBL] [Abstract][Full Text] [Related]
34. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
35. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
37. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
[TBL] [Abstract][Full Text] [Related]
38. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Bastos-Oreiro M; Gutierrez A; Iacoboni G; López Corral L; Reguera JL; Abrisqueta P; Delgado J; Terol MJ; Hernani R; Martínez N; Ortíz V; Bailen R; Gomez-Centurión I; Caballero A; Sanz J; Guerra Domínguez L; Luzardo H; Mussetti A; Jiménez-Ubieto A; Sancho JM; Sureda A; Pérez A; Barba P; Kwon M; Martín García-Sancho A
Transplant Cell Ther; 2023 Dec; 29(12):747.e1-747.e10. PubMed ID: 37659694
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
40. The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.
Kyriakou C; Boumendil A; Finel H; Nn Norbert Schmitz ; Andersen NS; Blaise D; Chevallier P; Browne P; Malladi R; Niederwieser D; Pagliuca A; Kroschinsky F; Montoto S; Dreger P;
Biol Blood Marrow Transplant; 2019 Jan; 25(1):86-93. PubMed ID: 30219698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]